Novartis arbeider for å skape økt verdi for pasienter og våre samarbeidspartnere innen helsevesenet. Vi vil påvirke menneskers liv i en positiv retning gjennom å oppdage, utvikle og markedsføre nye produkter for å helbrede sykdommer og forbedre menneskers livskvalitet.

Nedenfor finner du et utvalg av studier som er gode og viktige innen temaene:

  • Migrene (prevalens og sykdomsbyrde)
  • CGRP
  • Erenumab (Aimovig)

 

Studier om migrene (prevalens og sykdomsbyrde)

The global burden of headache →
Saylor D. Steiner T.J. Semin Neurol. 2018 Apr;38(2):182-190. Epub 2018 May 23.

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018 Nov 10;392(10159):1789-1858.

 

Studier om CGRP

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment →
Edvinsson L. Br J Ciin Pharmacol. 2015 Aug: 80(2): 193-199.

Calcitonin gene-related peptide (CGRP): a new target for migraine →
Russo AF, Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8

 

Studier om erenumab (Aimovig)

Kronisk migrene (CM):

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised. double-blind, placebo-controlled phase 2 trial →
Tepper S et al, The Lancet, Jun 2017, issue 6, P425-434.
Denne er også animert. Se her. →

 

Erenumab hos pasienter med kronisk migrene (CM) med medikamentoverforbruk:

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial →
Tepper SJ et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 Apr 17;10.

 

Episodisk migrene (EM)

A Controlled Trial of Erenumab for Episodic Migraine →
Goadsby P.J. Reuter U, Hallström Y. Broessner G. Bonner J.H, Zhang F. Sapra S. Picard H, Mikol D.D, Lenz R.A, N Engl J Med 2017; 377:2123-2132.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study →
Reuter U et al.The Lancet, Nov 2018. issue 10161. P2280-2287.

Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study →
Ashina M et al. Neurology. 2017 Sep 19;89(12):1237-1243.

 

Tre års sikkerhetsdata:

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

Ashina et al. Cephalalgia. 2019 May. https://doi.org/10.1177/0333102419854082
 

NO1910743702
×

Medical Information Request

×

Ask Speakers